Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C179625> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- NCIT_C179625 IAO_0000115 "A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating, anti-viral and antineoplastic activities. Upon administration,dresbuxelimab targets and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. In addition, dresbuxelimab may stimulate the production of anti-SARS-CoV-2 antibodies from B-cells which may lead to the rapid clearance of the virus. Also, by inhibiting CD73, extracellular ATP levels are increased, which induces the production of interferon-beta, and may enhance the cellular resistance to viral infection and may trigger apoptosis of virus-infected cells. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME)." @default.
- NCIT_C179625 NCIT_A7 NCIT_C114927 @default.
- NCIT_C179625 NCIT_NHC0 "C179625" @default.
- NCIT_C179625 NCIT_P106 "Amino Acid, Peptide, or Protein" @default.
- NCIT_C179625 NCIT_P106 "Immunologic Factor" @default.
- NCIT_C179625 NCIT_P108 "Dresbuxelimab" @default.
- NCIT_C179625 NCIT_P208 "CL1662167" @default.
- NCIT_C179625 NCIT_P210 "2550560-20-6" @default.
- NCIT_C179625 NCIT_P319 "QR3A4G4VHU" @default.
- NCIT_C179625 NCIT_P322 "FDA" @default.
- NCIT_C179625 NCIT_P322 "GDC" @default.
- NCIT_C179625 NCIT_P399 "804818" @default.
- NCIT_C179625 NCIT_R124 NCIT_C17710 @default.
- NCIT_C179625 NCIT_R124 NCIT_C17828 @default.
- NCIT_C179625 NCIT_R124 NCIT_C18219 @default.
- NCIT_C179625 NCIT_R124 NCIT_C19986 @default.
- NCIT_C179625 NCIT_R124 NCIT_C40474 @default.
- NCIT_C179625 normalizedInformationContent "100" @default.
- NCIT_C179625 referenceCount "1" @default.
- NCIT_C179625 hasExactSynonym "AK 119" @default.
- NCIT_C179625 hasExactSynonym "AK-119" @default.
- NCIT_C179625 hasExactSynonym "AK119" @default.
- NCIT_C179625 hasExactSynonym "Anti-CD73 Monoclonal Antibody AK119" @default.
- NCIT_C179625 hasExactSynonym "DRESBUXELIMAB" @default.
- NCIT_C179625 hasExactSynonym "Dresbuxelimab" @default.
- NCIT_C179625 inSubset NCIT_C128784 @default.
- NCIT_C179625 inSubset NCIT_C157711 @default.
- NCIT_C179625 inSubset NCIT_C157712 @default.
- NCIT_C179625 inSubset NCIT_C173381 @default.
- NCIT_C179625 inSubset NCIT_C173383 @default.
- NCIT_C179625 inSubset NCIT_C176424 @default.
- NCIT_C179625 inSubset NCIT_C63923 @default.
- NCIT_C179625 type Class @default.
- NCIT_C179625 isDefinedBy ncit.owl @default.
- NCIT_C179625 label "Dresbuxelimab" @default.
- NCIT_C179625 subClassOf NCIT_C129820 @default.
- NCIT_C179625 subClassOf NCIT_C129821 @default.
- NCIT_C179625 subClassOf NCIT_C129822 @default.
- NCIT_C179625 subClassOf NCIT_C176988 @default.
- NCIT_C179625 subClassOf NCIT_C179625 @default.
- NCIT_C179625 subClassOf NCIT_C1908 @default.
- NCIT_C179625 subClassOf NCIT_C1909 @default.
- NCIT_C179625 subClassOf NCIT_C201133 @default.
- NCIT_C179625 subClassOf NCIT_C20401 @default.
- NCIT_C179625 subClassOf NCIT_C274 @default.
- NCIT_C179625 subClassOf NCIT_C307 @default.
- NCIT_C179625 subClassOf NCIT_C308 @default.